Whether a patient with hepatitis B can receive the New Crown vaccine will need to be determined based on the patient’s own condition and liver biochemical indicators. If a patient is unsure whether he or she can receive the New Crown vaccine, he or she needs to consult a physician from the Department of Infectious Diseases or the Department of Hepatology to help analyze and determine. If the patient’s condition is stable, the liver biochemical indicators are normal, and there are no other contraindications for New Crown vaccination, the New Crown vaccine can be administered even during antiviral treatment. However, if the disease is active and the liver biochemical indicators are abnormal, vaccination with the New Crown vaccine is not recommended because such patients may be aggravated if they receive the New Crown vaccine. It is recommended to wait until the liver biochemistry is normal and the disease is stable before vaccination. In addition, vaccination with the New Crown vaccine is also not recommended for patients who are receiving immunosuppressive therapy, as their own immune system may not recognize the vaccine, resulting in vaccination failure. After vaccination, patients with hepatitis B should be observed at the site for 30 minutes after vaccination, just like other people who receive the vaccine. Pay attention to rest, drink more water, avoid drinking alcohol and strong tea and coffee, avoid eating spicy and stimulating foods, and avoid seafood to avoid triggering allergic reactions. Ensure sufficient sleep and avoid exertion. Adverse reactions such as fever, diarrhea, dizziness, headache, local swelling and pain may occur after inoculation. If mild adverse reactions occur, they can be observed and generally do not require treatment. If the adverse reaction is serious or lasts for a long time, go to the hospital as soon as possible.